MK-677 vs Ipamorelin: Oral Small Molecule vs Selective Peptide Secretagogue

MK-677 and ipamorelin both stimulate growth hormone through the same receptor, the ghrelin (growth hormone secretagogue) receptor, but they are very different drugs. MK-677 is an oral, long-acting small molecule with randomized human trials showing sustained GH and IGF-1 increases along with appetite, fluid-retention, glucose, and heart-failure concerns. Ipamorelin is a short-acting synthetic pentapeptide given parenterally, notable for selectivity (it did not raise cortisol or ACTH in animal studies), with a much smaller human evidence base. Neither is FDA-approved; FDA lists MK-677 in 503A Category 2, and ipamorelin is not on FDA's 503A category list.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

MK-677 vs Ipamorelin: Comparison Table

Same Receptor, Different Molecules

Both compounds act at the growth hormone secretagogue receptor, a G-protein-coupled receptor in the pituitary and hypothalamus that Merck scientists cloned in 1996 [2]. Ghrelin is its natural ligand.

MK-677 was built to be an orally active, non-peptide agonist of that receptor. Because it is a small molecule, it survives the gut and acts for many hours, producing sustained increases in GH and IGF-1 with daily oral use [3, 4]. The library entry is at MK-677 (Ibutamoren).

Ipamorelin came out of a Novo Nordisk chemistry program as a five-amino-acid peptide derived from the GHRP family [1]. Like other peptides it is not orally bioavailable in a meaningful way and is given by a parenteral route. In healthy male volunteers, it produced a single episode of GH release peaking at about 40 minutes, with a short terminal half-life of about 2 hours [5].

The practical consequence is a difference in the shape of GH exposure: MK-677 produces a sustained elevation, while ipamorelin produces a discrete pulse.

Selectivity: Ipamorelin's Distinguishing Feature

Earlier GH-releasing peptides such as GHRP-2 and GHRP-6 also raise ACTH and cortisol. Ipamorelin was described as the first selective secretagogue because, in swine, it released GH without significantly raising ACTH or cortisol, even at exposures more than 200-fold above its effective level for GH release; it also did not affect FSH, LH, prolactin, or TSH [1]. That finding is from animal pharmacology, not human trials.

MK-677, by comparison, raised cortisol modestly over a year in older adults [4]; in obese young men the cortisol effect was transient [3]. For a similar comparison within the peptide family, see GHRP-2 vs GHRP-6.

Evidence Base: Very Different Depths

MK-677 has the deeper human record:

• A two-year randomized trial in 65 healthy older adults found increased fat-free mass but no change in strength or function, and no change in visceral fat [4].
• An eight-week randomized trial in 24 obese men found increased fat-free mass and impaired glucose tolerance [3].
• A phase IIb hip-fracture trial in 123 patients improved IGF-1 but not most functional measures, and stopped early for a congestive heart failure signal [6].
• A 12-month trial in 563 patients with Alzheimer's disease showed no effect on progression [7].

Ipamorelin has much less:

• A pharmacokinetic and pharmacodynamic study in healthy male volunteers characterized its GH response and short half-life [5].

• A phase 2 randomized trial in 114 bowel-resection patients tested it for postoperative ileus. It was well tolerated, but time to first tolerated meal did not differ significantly from placebo [8].
• There are no published randomized trials of ipamorelin for body composition, aging, or fat loss, which are the uses it is most often discussed for.

Put simply, MK-677's evidence tells you a fair amount about both its effects and its risks. Ipamorelin's tells you about its pharmacology and short-term tolerability, but not whether it achieves the outcomes it is marketed for.

Side Effects Compared

MK-677. In randomized trials: increased appetite, transient mild lower-extremity edema, muscle pain, weight gain, higher fasting glucose and reduced insulin sensitivity, and a modest cortisol increase [4]; impaired glucose tolerance in obese men [3]; and a congestive heart failure signal that ended the hip-fracture trial early [6].

Ipamorelin. In the postoperative ileus trial, treatment-emergent adverse events were no more frequent than placebo (87.5% vs 94.8%), and the drug was described as well tolerated over up to 7 days [8]. That trial was short and in hospitalized surgical patients, so it does not establish long-term safety. Reviews of GH-axis peptides used outside regulatory oversight describe class effects such as appetite changes, fluid retention, and dysglycemia, plus product-quality concerns [9].

The key difference for patient selection: the metabolic and fluid-retention signals for MK-677 come from controlled trials, while the absence of such signals for ipamorelin mostly reflects the absence of long-term trials.

Regulatory Status in 2026

Neither compound is FDA-approved. FDA lists MK-677 (ibutamoren mesylate) in 503A Category 2, substances that raise significant safety risks; ipamorelin does not appear in any category on FDA's list updated May 14, 2026. Confirm current status on our FDA peptide status tracker and with your compounding pharmacy. Neither was on the July 2026 PCAC agenda. Both are prohibited in sport as growth hormone secretagogues.

Frequently Asked Questions

What is the difference between MK-677 and ipamorelin?

MK-677 is an oral, long-acting small molecule; ipamorelin is a short-acting peptide given by a parenteral route. Both activate the ghrelin receptor to release growth hormone, but MK-677 produces sustained elevation while ipamorelin produces a single pulse.

Is MK-677 stronger than ipamorelin?

They are not directly comparable, because no head-to-head human trial exists. MK-677 has trial data showing sustained GH and IGF-1 increases; ipamorelin's human data are limited to a PK/PD study and a postoperative ileus trial.

Which has fewer side effects, MK-677 or ipamorelin?

MK-677 has well-documented side effects from randomized trials, including appetite, edema, higher glucose, and a heart-failure signal in hip-fracture patients. Ipamorelin was well tolerated in a short surgical trial, but its long-term safety has not been studied.

Can MK-677 and ipamorelin be used together?

There are no published studies of the combination. Because both act on the same receptor, combining them has no established evidence base, and any treatment decision belongs to the prescribing clinician.

Are MK-677 and ipamorelin FDA approved?

No. MK-677 is in FDA's 503A Category 2 and ipamorelin is not on FDA's 503A category list. See our FDA peptide status tracker for current status.

References

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PubMed
2. Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-7. PubMed
3. Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-9. PubMed
4. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11. PubMed
5. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6. PubMed
6. Adunsky A, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53(2):183-9. PubMed
7. Sevigny JJ, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-8. PubMed
8. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. PubMed
9. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with licensed 503A partner pharmacies; prescribers can start at For Providers.